ALL-MED Specialistyczna Opieka Medyczna. Medyczny Instytut Badawczy
- Address
- lock Available on a paid plan
Immune System Diseases
The ALL-MED Specialistyczna Opieka Medyczna. Medyczny Instytut Badawczy is conducting studies that target disorders of the immune system, focusing on severe asthma phenotypes and chronic urticaria.
- Chronic Spontaneous Urticaria
- Severe Asthma
- Severe asthma with an eosinophilic phenotype
Trials aim to evaluate the safety and efficacy of emerging biologic therapies, offering potential new treatment options for patients whose conditions are difficult to control with standard care.
Otorhinolaryngologic Diseases
Research at the site emphasizes allergic diseases of the nose and eyes, investigating innovative approaches to reduce symptoms caused by seasonal and perennial allergens.
- Birch Pollen-induced Allergic Rhinoconjunctivitis
- Birch pollen induced allergic rhinitis or rhinoconjunctivitis
- Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma induced by House Dust Mite (HDM) Allergy
- Perennial Allergic Rhinitis (PAR)
- Seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure
- Seasonal allergic rhinitis and/or rhinoconjunctivitis
The goal is to assess the clinical benefit of subcutaneous allergen immunotherapy and related treatments, improving quality of life for individuals suffering from chronic nasal and ocular allergy.
Respiratory Tract Diseases
The institute’s respiratory program concentrates on severe asthma, especially forms linked to eosinophilic inflammation, seeking to broaden therapeutic options.
- Severe Asthma
- Severe asthma with an eosinophilic phenotype
Ongoing studies evaluate novel anti‑IL-5 and anti‑IL-4 agents for their ability to reduce exacerbations and improve lung function in patients with uncontrolled disease.
Skin and Connective Tissue Diseases
Investigations into dermatologic immune conditions focus on chronic urticaria, a condition marked by recurrent hives and itching.
- Chronic Spontaneous Urticaria
The research assesses the effectiveness of new monoclonal antibody treatments compared with placebo, targeting symptom relief and disease control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 40 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ALL-MED Specialistyczna Opieka Medyczna. Medyczny Instytut Badawczy
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Mannan-Conjugated Betula Pendula Pollen Allergoid in Birch Pollen-Induced Allergic Rhinitis | CCDRD Cooperative Clinical Drug Research and Development AG, ClinCompetence Cologne GmbH, Inmunotek S.L. | Phase III | Not Recruiting | Feb 2024 | Jun 2024 |
IMP list
lock Showing 1 of 40 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Histamine Dihydrochloride | 2 | Unknown | 2024-08-22 | 2024-09-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.